Your browser doesn't support javascript.
loading
Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies.
Kulasekararaj, Austin G; Griffin, Morag; Langemeijer, Saskia; Usuki, Kensuke; Kulagin, Alexander; Ogawa, Masayo; Yu, Ji; Mujeebuddin, Arshad; Nishimura, Jun-Ichi; Lee, Jong Wook; Peffault de Latour, Régis.
Afiliação
  • Kulasekararaj AG; Department of Haematological Medicine, King's College Hospital, National Institute for Health Research and Wellcome King's Clinical Research Facility and King's College London, London, UK.
  • Griffin M; NHS Teaching Hospitals, Leeds, UK.
  • Langemeijer S; Radboudumc, Nijmegen, Netherlands.
  • Usuki K; NTT Medical Center Tokyo, Tokyo, Japan.
  • Kulagin A; RM Gorbacheva Research Institute, Pavlov University, St Petersburg, Russia.
  • Ogawa M; Alexion, AstraZeneca Rare Disease, Boston, Massachusetts, USA.
  • Yu J; Alexion, AstraZeneca Rare Disease, Boston, Massachusetts, USA.
  • Mujeebuddin A; Alexion, AstraZeneca Rare Disease, Boston, Massachusetts, USA.
  • Nishimura JI; Osaka University Graduate School of Medicine, Suita, Japan.
  • Lee JW; Department of Hematology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
  • Peffault de Latour R; Hôpital Saint-Louis AP-HP, Paris, France.
Eur J Haematol ; 109(3): 205-214, 2022 Sep.
Article em En | MEDLINE | ID: mdl-35502600

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hemoglobinúria Paroxística Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hemoglobinúria Paroxística Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article